Interim Report January – March 2018

Continued progress of the project portfolio  January - March 2018 · Net sales for the period amounted to SEK 52.3 million (26.2)  · Operating profit amounted to SEK 18.9 million (1.5)  · Profit for the period amounted to SEK 15.4 million (1.1)  · Earnings per share were SEK 0.18 (0.02)  · Cash flow from operating activities amounted to SEK -42.0 million (-38.4)  Key events during the period January – March 2018 · BioArctic’s patent was granted in the US and Japan for treatment of patients with complete spinal cord injury with a medical device, which is one of the